XILAPLUS® AF

0

We are proud to announce the publication of the clinical trial “Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children"

Santos J. et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.Expert Rev Gastroenterol Hepatol: 2020 Oct 19;1-7. doi: 10.1080/17474124.2021.1833715.

We are proud to announce the publication of the clinical trial “Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.”. While Oral Rehydration (ORS) is the main treatment of acute diarrhea in children, the addition of specific antidiarrheals may speed up the reduction of symptoms. In this clinical trial, children receiving xyloglucan/gelose (vegetal ingredients of Xilaplus AF) on top of the ORS, had significantly fewer diarrheic episodes than those who received ORS alone. The improvement of symptoms in the group on Xyloglucan/gelose was evident from 6 hours after the first dose.

Read more

Noventure presents its pediatric range at the 51st ESPGHAN Annual Meeting in Geneva, 09-12 May 2018

As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018. Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them approached Noventure´s stand to request information. Our innovative products intended for acute diarrhea (TASECTAN®, TASECTAN DUO® and XILAPLUS®) attracted a lot of interest from doctors.

Read more

Let's meet in..

2021, May 27

PharmaVenue Berlin

Read more

2021, Jun 02

ESPGHAN 6th World Congress

Read more

2021, Jun 14

euroPLX 76 Noordijk

Read more